The Success Stories

itm AG, a Bavarian company on the Canadian medical technology market

Medical application of radioactive isotopoes © kernfragen.de

Isotopen Technologie München AG (itm AG) was founded in 2004 in the immediate vicinity of the Garching research reactor, near Munich. The company produces new sorts of medical isotopes, used in medical imaging processes and as treatments for certain diseases. After several visits to Montreal as part of economic delegations from Bavaria, itm is now ready to introduce its first product line to the Canadian market, thanks to its local partner Draximage.

Itm-logoitm-Rhenium-PTA” is a new technology for the treatment of peripheral and cardiac endovascular diseases. “The product should be introduced on the Canadian market in the course of 2012”, says Oliver Buck, itm president. “We have been looking for the best way to enter the market for many years, and I am confident now that we seem to finally be there. Throughout the worldwide isotope crisis, which was triggered among other factors by the outfall of the Chalk River reactor, we have witnessed not only a new demand, but also more openness towards the use of new isotopes”, Mr. Buck happily points out.

“Finding new clients and partners takes time. On top of the support of our Canadian partner, we have always been able to count on the State of Bavaria Montreal Office, whith  their extended network. The excellent political connexions are of especially great importance in the Canadian public health sector.”